

Efavirenz + emtricitabine + tenofovir



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

ATC codes: [J05AR06](#)

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: 1C62.Z
INN	Efavirenz + emtricitabine + tenofovir
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
EML status history	First added in 2007 (TRS 946) Changed in 2021 (TRS 1035)
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	efavirenz + lamivudine + tenofovir (ATC codes: J05AR11)
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org ↗ Read more about patents. ↗

Wikipedia [Efavirenz + emtricitabine + tenofovir](#) [↗](#)

DrugBank [Efavirenz](#) [↗](#),
[Emtricitabine](#) [↗](#),
[Tenofovir disoproxil](#) [↗](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.

